Synonym
Guancydine; Guancidine; Guancidina; Guancidinum; CL-2422; CL 2422; CL2422
IUPAC/Chemical Name
(E)-2-cyano-1-(tert-pentyl)guanidine
InChi Key
VZVGEDRCVUKSEL-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H14N4/c1-4-7(2,3)11-6(9)10-5-8/h4H2,1-3H3,(H3,9,10,11)
SMILES Code
CCC(C)(N/C(N)=N/C#N)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Guancydine (Guancidine) is an antihypertensive agent.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
125.0 |
810.55 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
154.22
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Worcel M, Papadimitriou A, Meyer P. Blockade of the effects of angiotensin, oxytocin, norepinephrine, 5-hydroxytryptamine and acetylcholine by guancydine. J Pharmacol Exp Ther. 1971 Oct;179(1):42-6. PMID: 4328887.
2: Hărăgus ST, Uza G, Duncea C. Guancydine, a new hypotensive agent with complex action. Cor Vasa. 1977;19(3):214-9. PMID: 562730.
3: Clark DW, Goldberg LI. Guancydine: a new antihypertensive agent. Use with quinethazone and guanethidine or propranolol. Ann Intern Med. 1972 Apr;76(4):579-85. doi: 10.7326/0003-4819-76-4-579. PMID: 4565483.
4: Ellenbogen L, Chan PS, Cummings JF. Effects of guancydine on catecholamine synthesis storage and catabolism. Arch Int Pharmacodyn Ther. 1974 Jan;207(1):170-9. PMID: 4856856.
5: Gussin RZ, Stokey EH, Ronsberg MA, Malone LC, Cummings JR. The effect of guancydine on fluid and electrolyte excretion: a comparison with hydralazine and reserpine. Arch Int Pharmacodyn Ther. 1971 Jul;192(1):135-51. PMID: 5093183.
6: Sponer G, Mannesmann G, Bartsch W, Dietmann K. A method for evaluating postural hypotension in conscious rabbits as a model to predict effects of drugs in man. J Pharmacol Methods. 1981 Jan;5(1):53-8. doi: 10.1016/0160-5402(81)90102-9. PMID: 7265985.
7: Cummings JR, Welter AN, Grace JL Jr, Gray WD. Angiotensin blocking actions of guancydine. J Pharmacol Exp Ther. 1969 Dec;170(2):334-46. PMID: 4311323.
8: Goldberg LI. Current therapy of hypertension. A pharmacologic approach. Am J Med. 1975 Apr;58(4):489-94. doi: 10.1016/0002-9343(75)90121-7. PMID: 235841.
9: Villarreal H, Arcila H, Ramírez MA, Sierra P. Effect of guancydine on systemic and renal hemodynamics in arterial hypertension. Mayo Clin Proc. 1977 Jun;52(6):383-6. PMID: 325301.
10: Leonetti G, Bonazzi O, Grazi S, Ligresti A, Romano S, Zanchetti A. Cardiovascular and renal effects of acute administration of a new hypotensive compound, guancydine. Eur J Clin Pharmacol. 1971 Dec;4(1):1-9. doi: 10.1007/BF00568890. PMID: 4339486.
